Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19488489 | 0.85 | CDC7 (0.38) | SCN10ACDC7CCNE1CDK2ROCK1 | |
| SCHEMBL19488494 | 0.80 | — | — | |
| SCHEMBL10202476 | 0.80 | — | — | |
| SCHEMBL19488529 | 0.79 | CDC7 (0.40) | SCN10ACDC7CCNE1CDK2ROCK1 | |
| SCHEMBL13087671 | 0.77 | CDC7 (0.33) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL12332959 | 0.77 | SCN10A (0.34) | SCN10ACDC7CCNE1CDK2ROCK1 | |
| SCHEMBL19488597 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL2511260 | 0.76 | CDC7 (0.35) | SCN10ACDC7CCNE1CDK2ROCK1 | |
| SCHEMBL10201149 | 0.75 | NPC1 (0.36) | SCN10A | |
| SCHEMBL13221481 | 0.75 | NPC1 (0.36) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SCN10A 4625/4885CDC7 911/4885CCNE1 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.